Literature DB >> 17610079

Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs.

R Hadighi1, P Boucher, A Khamesipour, A R Meamar, G Roy, M Ouellette, M Mohebali.   

Abstract

Cutaneous leishmaniasis (CL) is a major health problem in endemic areas of Iran. The pentavalent antimony (SbV) based drug Glucantime is the first line of treatment for CL in Iran, but recently SbV-resistant Leishmania tropica isolates derived from unresponsive patients were reported. We show in this study that these resistant parasites are cross-resistant to the other SbV-containing drug Pentostam and at least for one isolate also to amphotericin B. However, these resistant isolates were shown to be sensitive to miltefosine and paromomycin. The latter two drugs could thus be useful alternatives for the treatment of leishmaniasis in Iran even for SbV-resistant isolates.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17610079     DOI： 10.1007/s00436-007-0638-0

Source DB:  PubMed          Journal:  Parasitol Res        ISSN： 0932-0113            Impact factor:   2.289


  25 in total

Review 1.  Advances in leishmaniasis.

Authors:  Henry W Murray; Jonathan D Berman; Clive R Davies; Nancy G Saravia
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

2.  Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal.

Authors:  Saskia Decuypere; Suman Rijal; Vanessa Yardley; Simonne De Doncker; Thierry Laurent; Basudha Khanal; François Chappuis; Jean-Claude Dujardin
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

3.  Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.

Authors:  R Lira; S Sundar; A Makharia; R Kenney; A Gam; E Saraiva; D Sacks
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

4.  A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death.

Authors:  Baptiste Vergnes; Benjamin Gourbal; Isabelle Girard; Shyam Sundar; Jolyne Drummelsmith; Marc Ouellette
Journal:  Mol Cell Proteomics       Date:  2006-10-17       Impact factor: 5.911

5.  Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models.

Authors:  Anuradha Dube; Nasib Singh; Shyam Sundar; Neeloo Singh
Journal:  Parasitol Res       Date:  2005-05-03       Impact factor: 2.289

6.  Characterization of Leishmania infection in rodents from endemic areas of the Islamic Republic of Iran.

Authors:  M Mohebali; E Javadian; M R Yaghoobi-Ershadi; A A Akhavan; H Hajjaran; M R Abaei
Journal:  East Mediterr Health J       Date:  2004 Jul-Sep       Impact factor: 1.628

7.  Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models.

Authors:  G Roy; C Dumas; D Sereno; Y Wu; A K Singh; M J Tremblay; M Ouellette; M Olivier; B Papadopoulou
Journal:  Mol Biochem Parasitol       Date:  2000-10       Impact factor: 1.759

Review 8.  Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004.

Authors:  Piero L Olliaro; Philippe J Guerin; Sibylle Gerstl; Astrid Aga Haaskjold; John-Arne Rottingen; Shyam Sundar
Journal:  Lancet Infect Dis       Date:  2005-12       Impact factor: 25.071

9.  Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.

Authors:  Ricardo Rojas; Liliana Valderrama; Mabel Valderrama; Maria X Varona; Marc Ouellette; Nancy G Saravia
Journal:  J Infect Dis       Date:  2006-04-07       Impact factor: 5.226

10.  Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.

Authors:  M Ephros; A Bitnun; P Shaked; E Waldman; D Zilberstein
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191
View more
  36 in total

1.  Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis.

Authors:  Glenn Wortmann; Michael Zapor; Roseanne Ressner; Susan Fraser; Josh Hartzell; Joseph Pierson; Amy Weintrob; Alan Magill
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

2.  Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan.

Authors:  Yoav Keynan; Oscar E Larios; Marni C Wiseman; Marie Plourde; Marc Ouellette; Ethan Rubinstein
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-11       Impact factor: 2.471

3.  Intralesional Pentamidine: A Novel Therapy for Single Lesions of Bolivian Cutaneous Leishmaniasis.

Authors:  Jaime Soto; David Paz; Daniela Rivero; Paula Soto; Jorge Quispe; Julia Toledo; Jonathan Berman
Journal:  Am J Trop Med Hyg       Date:  2016-02-22       Impact factor: 2.345

4.  Frequency of MDR1-related p-gp overexpression in Greek Leishmania isolates.

Authors:  Johannes Austrup; Pantelis Ntais; Vasiliki Christodoulou; Jean-Pierre Dedet; Francine Pratlong; Maria Antoniou
Journal:  Parasitol Res       Date:  2014-02-07       Impact factor: 2.289

5.  Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis.

Authors:  Anil Kumar Jaiswal; Prashant Khare; Sumit Joshi; Pramod Kumar Kushawaha; Shyam Sundar; Anuradha Dube
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

6.  Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis.

Authors:  Eglal I Amer; Maha M Eissa; Shereen F Mossallam
Journal:  J Parasit Dis       Date:  2014-08-31

7.  Effect of root bark extract of Berberis vulgaris L. on Leishmania major on BALB/c mice.

Authors:  Alireza Salehabadi; Mahdi Karamian; Motevalli Haghi Farzad; Mohammad Hasan Namaei
Journal:  Parasitol Res       Date:  2013-12-12       Impact factor: 2.289

8.  Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.

Authors:  Virgínia M Carregal; Juliane S Lanza; Daniel M Souza; Arshad Islam; Cynthia Demicheli; Ricardo T Fujiwara; Luis Rivas; Frédéric Frézard
Journal:  Parasitol Res       Date:  2019-08-10       Impact factor: 2.289

9.  In vitro antileishmanial activity of methanolic and aqueous extracts of Eucalyptus camaldulensis against Leishmania major.

Authors:  Seyyed Jafar Nosratabadi; Iraj Sharifi; Fariba Sharififar; Mehdi Bamorovat; Hamid Daneshvar; Mohammad Mirzaie
Journal:  J Parasit Dis       Date:  2013-11-12

10.  The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate.

Authors:  Azar Shokri; Iraj Sharifi; Ali Khamesipour; Nozar Nakhaee; Majid Fasihi Harandi; Jafar Nosratabadi; Maryam Hakimi Parizi; Mohammad Barati
Journal:  Parasitol Res       Date:  2011-08-17       Impact factor: 2.289
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.